Bio Integrates 2022 Track 2


How do we protect, progress and pivot our products for maximal value?

Welcome and opening remarks

MARTINO PICARDO | Chairman | Discovery Park

We are sorry that we had a few technical issues at the start of the day, so we only have the audio file of Martino’s opening remarks

A fireside chat with Andreas Wallnoefer

An interview with: ANDREAS WALLNOEFER | Partner & Investor | Jeito Capital
Interviewed by: MARTINO PICARDO | Chairman | Discovery Park

A fireside chat with Ruth McKernan CBE

An Interview with: Dr RUTH McKERNAN CBE | Neuroscientist, businesswoman and innovation leader
Interviewed by: TREVOR JONES CBE | Chairman and Board Member | e-Therapeutics, Respiratory Innovation Wales and Ascension Healthcare

Making your product fit for purpose

How are you responding to the increasing interest, pressure, regulation, and legislation around the ethics, provenance, and sustainability of products? Are you ready? Can you see market opportunities?


NAZNEEN RAHMAN CBE | Chief Executive Officer and NED| YewMaker and AstraZeneca


JOHN CLACK | VP, Manufacturing | COMPASS Pathways
LISA DITTMAR | Net Zero and Sustainable Supply Chain Lead | NHS England
RACHEL GRIFFITHS | Director, Technical Services | PCI Pharma Services
DAVE ENNIS |Vice President of Chemical Development | AstraZeneca

Protect at all costs

The costs of protecting your IP can ramp up rapidly. How can you plan your IP strategy efficiently and cost-effectively?


JAMES FRY | Partner and Head of Life Sciences | Mills & Reeve


AHMED BOUZIDI | Vice-President Biotech | ProductLife Group
EMMANUELLE ASTOUL | Head of Licensing | Transine Therapeutics
RAMINDERPAL SINGH | Chief Executive Officer and co-Founder | Ltd
MARC WILKINSON | Partner, Patent and Trade Mark Attorney | J A Kemp
CARL EDWARDS | Head of IP & Commercial and LD3 Manager | University of Leicester

Get out(sourced)!

Finding the right outsourcing partners to help develop and scale your products is critical to milestones and budgets. How can we ensure we are working with the right partners at the right time?


PAUL BRANTHWAITE | Senior Partner & Client Liaison | tranScrip


MAURA MCARDLE | Head Of Business Development (Europe) | SGS QuayPharma
PETER MACLENNAN | Chief Executive Officer | Tailored Clinical Research Solutions
STEVE TRIM | Founder / Chief Scientific Officer | Venomtech
CLAIRE PATTERSON | Senior Principal Scientist | SEDA Pharmaceutical Development Services
BODIL VAN NIEL | Director of Chemistry | Charles River Laboratories
ALAN LAHAISE | Vice President, Business Development, Manufacturing and EMEA Clinical Services | PCI Services

Been there, done that

Success stories from those who have felt the fire at their feet, bridged the valley of death, scaled and sold their companies.


RICHARD WEAVER | Senior Vice President, Pre-clinical Development | Sygnature Discovery


JO CRAIG | Senior Vice President CMC | NeRRe Therapeutics
MARK MCHALE | Chief Scientific Officer | Oak Hill Bio
JOHN VON BENECKE | Chief Executive Officer | Locate Bio
NICK SMITH | Site Director, Alderley Park |
Charles River Laboratories
CRAIG FOX | Operating Partner (Lifesciences) | Oxford Science Enterprises

Fuelling the genetic medicine revolution

Nucleic acid (mRNA and DNA) vaccines aren’t necessarily new, but recent outcomes during the COVID pandemic are stimulating a renaissance in the wider biopharmaceutical industry as drug manufacturers turn their attention to issues such as speed-to-market, faster scale-up and, of course, safety. For commercial success, however, key challenges such as long lead times and high capital costs need to be overcome. Novel technologies such as synthetic vectors are not only able to target genes with a size and complexity that current technologies can’t, they may also offer solutions to current capacity and supply chain constraints. So, are the days of fermentation over? Is this a new era of global-scale mass production for cold-chain-free gene therapies and, perhaps most importantly from a regulatory standpoint, are these advanced therapeutics biological anymore?


JONATHAN APPLEBY | Chief Scientific Officer | Cell and Gene Therapy Catapult


HELEN HORTON | Chief Research Officer |  Touchlight
KEITH WILLIAMS| Co-founder Managing Director | Phenotypeca
JOSHUA BLIGHT | Chief Executive Officer & Co-Founder |  Baseimmune
KARIN SCHMITT | Chief Business Officer | Mogrify
BAKUL GUPTA | Chief Executive Officer and Co-founder | ImmTune Therapies

Closing remarks

MARTINO PICARDO | Chairman | Discovery Park